NASDAQ:IKNA

Ikena Oncology - IKNA Stock Forecast, Price & News

$4.20

-0.06 (-1.41%)

(As of 02/1/2023 12:00 AM ET)

Add

Compare

Today's Range: $4.20
▼
$4.45
50-Day Range: $2.22
▼
$4.48
52-Week Range: $1.94
▼
$11.79

Volume: 1.51 million shs
Average Volume: 26,963 shs
Market Capitalization: $152.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.00

Institutional Ownership

Ikena Oncology MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 352.4% Upside
$19.00 Price Target
Short Interest: Bearish
8.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.02) to ($2.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

841st out of 1,053 stocks

Biological Products, Except Diagnostic Industry

138th out of 170 stocks

3.5

Analyst's Opinion

Consensus Rating
Ikena Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, Ikena Oncology has a forecasted upside of 352.4% from its current price of $4.20.
Amount of Analyst Coverage
Ikena Oncology has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.69% of the float of Ikena Oncology has been sold short.
Short Interest Ratio / Days to Cover
Ikena Oncology has a short interest ratio ("days to cover") of 20.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Ikena Oncology has recently increased by 3.05%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Ikena Oncology does not currently pay a dividend.
Dividend Growth
Ikena Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IKNA.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Ikena Oncology this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ikena Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.81% of the stock of Ikena Oncology is held by insiders.
Percentage Held by Institutions
72.40% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ikena Oncology are expected to decrease in the coming year, from ($2.02) to ($2.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ikena Oncology is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ikena Oncology is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ikena Oncology has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ikena Oncology (NASDAQ:IKNA) Stock

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Receive IKNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

IKNA Stock News Headlines

January 29, 2023 | americanbankingnews.com

Ikena Oncology (NASDAQ:IKNA) Trading 9.3% Higher

January 15, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Achilles Therapeutics (ACHL), Novan (NOVN) and Ikena Oncology (IKNA)

February 2, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now!

December 22, 2022 | finance.yahoo.com

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Invest In Growth?

November 28, 2022 | finance.yahoo.com

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

November 22, 2022 | finance.yahoo.com

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 11, 2022 | finance.yahoo.com

Ikena Oncology Third Quarter 2022 Earnings: Beats Expectations

November 10, 2022 | finance.yahoo.com

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

February 2, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

November 7, 2022 | finanznachrichten.de

Ikena Oncology, Inc.: Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

November 7, 2022 | msn.com

Ikena Oncology: Q3 Earnings Insights

November 7, 2022 | finance.yahoo.com

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

November 7, 2022 | finance.yahoo.com

Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates

November 7, 2022 | finance.yahoo.com

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

October 26, 2022 | finance.yahoo.com

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

October 18, 2022 | finance.yahoo.com

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

October 5, 2022 | finance.yahoo.com

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

September 22, 2022 | finance.yahoo.com

Investors one-year losses grow to 71% as the stock sheds US$33m this past week

September 9, 2022 | morningstar.com

Ikena Oncology Inc IKNA Sustainability

September 6, 2022 | finance.yahoo.com

Ikena Oncology to Participate in September 2022 Investor Conferences

August 16, 2022 | nasdaq.com

Earnings Update: Ikena Oncology, Inc. (NASDAQ:IKNA) Just Reported And Analysts Are Trimming Their Forecasts

August 13, 2022 | uk.investing.com

Ikena Oncology, Inc. Misses Q2 EPS by 8c

August 12, 2022 | finance.yahoo.com

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

August 11, 2022 | msn.com

Ikena Oncology: Q2 Earnings Insights

August 11, 2022 | finance.yahoo.com

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

August 11, 2022 | finance.yahoo.com

Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates

July 14, 2022 | finance.yahoo.com

How Much Of Ikena Oncology, Inc. (NASDAQ:IKNA) Do Institutions Own?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IKNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

IKNA Company Calendar

Last Earnings: 11/07/2022
Today: 2/02/2023
Next Earnings (Estimated): 3/16/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IKNA
CUSIP: N/A
CIK: 1835579
Web: ikenaoncology.com
Phone: 857-273-8343
Fax: N/A
Employees: 67
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.00
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +352.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,120,000.00
Net Margins: N/A
Pretax Margin: -172.89%
Return on Equity: -28.27%
Return on Assets: -23.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.11
Quick Ratio: 7.11

Sales & Book Value

Annual Sales: $30.99 million
Price / Sales: 4.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.78 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 36,260,000
Free Float: 34,513,000
Market Cap: $152.29 million
Optionable: Not Optionable
Beta: 0.80

Key Executives

Dr. Mark Manfredi Ph.D. (Age 51)
Pres. CEO & Director
Comp: $795k

Dr. Sergio L. Santillana M.B.A. (Age 59)
M.D., M.Sc., MSc, Chief Medical Officer
Comp: $616k

Dr. Jotin Marango M.D. (Age 43)
Ph.D., CFO & Head of Corp. Devel.

Dr. Michelle Zhang Ph.D.
Chief Scientific Officer

Ms. Samantha Vuksanic
Head of HR

Mr. Jeffrey Ecsedy Ph.D. (Age 52)
Chief Devel. Officer

Mr. Alfredo Castro Ph.D.
Exec. VP of Discovery

Mr. Alexander Constan Ph.D.
Sr. VP of Non Clinical Safety & DMPK

Ms. Jennifer Schroeder
Sr. VP of Clinical Devel. Operations

Mr. Evan A. Hecker Ph.D.
Sr. VP & Head of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

IKNA Stock - Frequently Asked Questions

Should I buy or sell Ikena Oncology stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IKNA shares.
View IKNA analyst ratings or view top-rated stocks.
What is Ikena Oncology's stock price forecast for 2023?: 2 brokerages have issued 1 year price objectives for Ikena Oncology's stock. Their IKNA share price forecasts range from $16.00 to $22.00. On average, they expect the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 352.4% from the stock's current price.
View analysts price targets for IKNA or view top-rated stocks among Wall Street analysts.
How have IKNA shares performed in 2023?: Ikena Oncology's stock was trading at $2.66 on January 1st, 2023. Since then, IKNA stock has increased by 57.9% and is now trading at $4.20.
View the best growth stocks for 2023 here.
When is Ikena Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our IKNA earnings forecast.

How were Ikena Oncology's earnings last quarter?: Ikena Oncology, Inc. (NASDAQ:IKNA) released its earnings results on Monday, November, 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.02. The firm earned $6.40 million during the quarter, compared to analyst estimates of $3.83 million.
When did Ikena Oncology IPO?: (IKNA) raised $125 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO.
What is Ikena Oncology's stock symbol?: Ikena Oncology trades on the NASDAQ under the ticker symbol "IKNA."
How do I buy shares of Ikena Oncology?: Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ikena Oncology's stock price today?: One share of IKNA stock can currently be purchased for approximately $4.20.
How much money does Ikena Oncology make?: Ikena Oncology (NASDAQ:IKNA) has a market capitalization of $152.29 million and generates $30.99 million in revenue each year. The company earns $-34,120,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.
How can I contact Ikena Oncology?: Ikena Oncology's mailing address is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. The official website for the company is ikenaoncology.com. The company can be reached via phone at 857-273-8343 or via email at info@ikenaoncology.com.

This page (NASDAQ:IKNA) was last updated on 2/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ikena Oncology - IKNA Stock Forecast, Price & News

Ikena Oncology MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Ikena Oncology (NASDAQ:IKNA) Stock

IKNA Stock News Headlines

IKNA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IKNA Stock - Frequently Asked Questions

Overall MarketRank^™